Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved

Oct.11.2025
Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Altria’s new nicotine pouch On! PLUS™ is slated to launch in the U.S. on October 14, debuting in North Carolina, Texas, and Florida. The product uses NICOSILK™ technology and will offer multiple nicotine strengths. FDA approval has not yet been granted, but Helix says it is proceeding in line with compliance requirements.

Key Takeaways:
 

· Launch Date: Official U.S. release on October 14, 2025.

· Initial Markets: North Carolina, Texas, and Florida.

· Product Features: Spit-free design featuring NICOSILK™ mesh technology.

· Regulatory Status: PMTA submission to the FDA exceeds 25,000 pages.

· Market Context: ZYN remains the only FDA-authorized brand; competition is heating up.

 


2Firsts, October 14, 2025 — Altria’s nicotine pouch brand On! is set to officially enter the U.S. market. The new product, On! PLUS™, developed by Altria subsidiary Helix, will first roll out in North Carolina, Texas, and Florida.

 

The news first surfaced in the Reddit nicotine pouch community (r/NicotinePouch), where multiple users said they had received launch notification emails from On!. According to shared posts, initial flavors include Mint, Wintergreen, and Tobacco, with some users noting that onnicotine.com may offer mail-order purchases.
 

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Reddit discussion on the U.S. October 14 launch of On! PLUS | Source: Reddit

 

Consumers generally expressed enthusiasm for the new product and compared it to On! offerings in Europe. Some users described the European On! pouches as “soft-bodied with a clean taste,” praising flavors like Smooth Mint and Watermelon Mint.

 

 

Helix moves first on market deployment

 

 

As early as August 22, 2Firsts observed that Altria announced via its official account on X (formerly Twitter) that Helix would launch On! PLUS™ this fall. Made at the company’s Richmond, Virginia facility, the product targets adult consumers 21+, offers 6 mg, 9 mg, and 12 mg nicotine strengths, and features the proprietary NICOSILK™ mesh technology to provide U.S. consumers a more convenient smoke-free alternative.

 

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
Post from Altria’s X account on August 22 | Source: Altria on X

 

Although FDA authorization has not yet been granted, Altria plans to proceed in accordance with compliance procedures. Helix submitted a PMTA in June 2024 exceeding 25,000 pages, authored by more than 50 experts and covering scientific and compliance studies in line with the Tobacco Control Act.

 

Altria stated that while the FDA review has surpassed the statutory 180-day timeframe, the company continues to follow all compliance steps, including ingredient disclosures, facility inspections, and marketing material submissions.

 

Altria’s Nicotine Pouch Rollout in the U.S.: On! PLUS May Launch on October 14, Not Yet FDA-Approved
On! PLUS series nicotine pouches | Photo: 2Firsts at InterTabac, Dortmund, Germany, September

 

 

Industry backdrop: competition in smoke-free alternatives intensifies

 

 

At present, ZYN—owned by Philip Morris International (PMI)—is the only nicotine pouch brand authorized by the FDA for U.S. sales. No other brand has received full marketing authorization.

 

Notably, just one day before Altria announced On! PLUS™ (on August 21), Reuters reported that British American Tobacco (BAT) plans a U.S. pilot for its disposable synthetic-nicotine e-cigarette Vuse One, expected to launch in late September in South Carolina, Florida, and Georgia. The overlapping timelines and regions with On! PLUS™ suggest a new wave of competition in the U.S. nicotine alternatives market.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
Make Your Brand Understood by the People Who Matter
Make Your Brand Understood by the People Who Matter
Feb.02
Malaysian Sabah GOF seizes e-cigarettes, vapes and e-liquids worth over  USD 156,333 in seven-district operation
Malaysian Sabah GOF seizes e-cigarettes, vapes and e-liquids worth over USD 156,333 in seven-district operation
In Sabah, Malaysia’s General Operations Force (GOF) seized thousands of e-cigarette devices, vapes and e-liquids worth more than RM635,000 and detained 23 people during a simultaneous integrated operation across seven districts.
Jan.19 by 2FIRSTS.ai
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands said in a statement on its website that John Rishton will join the board in July 2026 and assume the role of chair in December, succeeding current chair Thérèse Esperdy, who will retire at that time.
Jan.21 by 2FIRSTS.ai
Product | Detachable Battery + Dual-Battery System: RAZ VUE 50K Launches on U.S. Online Vape Channels
Product | Detachable Battery + Dual-Battery System: RAZ VUE 50K Launches on U.S. Online Vape Channels
RAZ has recently launched the RAZ VUE 50K on U.S. online vape channels, positioning it as the brand’s first disposable vape featuring a detachable battery. The device uses a dual-battery setup—an integrated 420mAh battery in the pod paired with a reusable 900mAh power bank—and is rated for up to approximately 50,000 puffs in Normal Mode.
Jan.16 by 2FIRSTS.ai
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
Kenya’s BAT Kenya resumes Velo nicotine pouches after citing regulatory clarity
BAT Kenya says it has resumed sales of Velo oral nicotine pouches after receiving regulatory clarity, reinforcing its push into non-combustible products as cigarette consumption falls.The company reported a 10% drop in turnover in 2025, with revenue closing at KSh23.2 billion (about $178.64 million), largely attributed to the growing presence of illegal tobacco products.
Mar.03 by 2FIRSTS.ai